NitroMed
Bedford
About NitroMed
NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Total funding: $51.3M
- Funding stage: M&A
- Last round: Series E (Aug 2003)
- Ticker: nasdaq:NTMD
- Website: nitromed.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/nitromed-1843988 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.